COMPASS PATHWAYS PLC (CMPS) Stock Price, Forecast & Analysis
USA - NASDAQ:CMPS - US20451W1018 - ADR
CMPS Key Statistics, Chart & Performance
The current stock price of CMPS is 5.29 USD. In the past month the price decreased by -17.47%. In the past year, price increased by 4.96%.
CMPS Latest News, Press Relases and Analysis
CMPS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.58 | 410.35B | ||
| AMGN | AMGEN INC | 15.36 | 180.89B | ||
| GILD | GILEAD SCIENCES INC | 15.29 | 155.35B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.03 | 111.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.44 | 73.66B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 890.14 | 59.51B | ||
| INSM | INSMED INC | N/A | 40.36B | ||
| NTRA | NATERA INC | N/A | 27.54B | ||
| BIIB | BIOGEN INC | 9.84 | 24.15B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.52 | 20.91B | ||
| INCY | INCYTE CORP | 16.42 | 20.58B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.49 | 14.30B |
Related stock screener links
About CMPS
Company Profile
Compass Pathways Plc is a biotechnology company, which provides mental health care services. The company is headquartered in Altrincham, Cheshire and currently employs 166 full-time employees. The company went IPO on 2020-09-18. The firm is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. The company commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. The company also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
Company Info
COMPASS PATHWAYS PLC
3Rd Floor, 1 Ashley Road
Altrincham CHESHIRE WA14 2DT GB
CEO: George Goldsmith
Employees: 166
Phone: 17166766461
COMPASS PATHWAYS PLC / CMPS FAQ
What does CMPS do?
Compass Pathways Plc is a biotechnology company, which provides mental health care services. The company is headquartered in Altrincham, Cheshire and currently employs 166 full-time employees. The company went IPO on 2020-09-18. The firm is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. The company commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. The company also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
Can you provide the latest stock price for COMPASS PATHWAYS PLC?
The current stock price of CMPS is 5.29 USD. The price decreased by -9.73% in the last trading session.
Does CMPS stock pay dividends?
CMPS does not pay a dividend.
How is the ChartMill rating for COMPASS PATHWAYS PLC?
CMPS has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does COMPASS PATHWAYS PLC belong to?
COMPASS PATHWAYS PLC (CMPS) operates in the Health Care sector and the Biotechnology industry.
What is COMPASS PATHWAYS PLC worth?
COMPASS PATHWAYS PLC (CMPS) has a market capitalization of 494.94M USD. This makes CMPS a Small Cap stock.
What is the Short Interest ratio of COMPASS PATHWAYS PLC (CMPS) stock?
The outstanding short interest for COMPASS PATHWAYS PLC (CMPS) is 6.75% of its float.
CMPS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CMPS. When comparing the yearly performance of all stocks, CMPS is one of the better performing stocks in the market, outperforming 77.47% of all stocks.
CMPS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CMPS. CMPS may be in some trouble as it scores bad on both profitability and health.
CMPS Financial Highlights
Over the last trailing twelve months CMPS reported a non-GAAP Earnings per Share(EPS) of -2.86. The EPS decreased by -30% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -92.84% | ||
| ROE | -631.31% | ||
| Debt/Equity | 0.49 |
CMPS Forecast & Estimates
16 analysts have analysed CMPS and the average price target is 15.91 USD. This implies a price increase of 200.79% is expected in the next year compared to the current price of 5.29.